1791. Deputy Sorca Clarke asked the Minister for Health to outline the current status of the reimbursement application for skyclarys (omaveloxolone) for the treatment of Friedreich’s ataxia; if she will provide a detailed update of ongoing engagement between the HSE and the manufacturer; and the way in which the commitments contained within the National Rare Disease Strategy 2025–2030 are being applied in this case, particularly in respect of timely and equitable access to licensed orphan medicines for patients with rare and ultra-rare conditions. [18960/26]

Summary

1791. Deputy Sorca Clarke asked the Minister for Health to outline the current status of the reimbursement application for skyclarys (omaveloxolone) for the treatment of Friedreich’s ataxia; if she will provide a detailed update of ongoing engagement between the HSE and the manufacturer; and the way in which the commitments contained within the National Rare Disease Strategy 2025–2030 are being applied in this case, particularly in respect of timely and equitable access to licensed orphan medicines for patients with rare and ultra-rare conditions. [18960/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 18 March 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.